The evolutionary pressure to merge the boundaries between pharmaceutical and biotechnology companies in order to survive, is increasing. The current view on the Indian biosimilars industry is that at some point in the near future, it will replicate the relative success of the Indian pharma generics industry, in the global markets. The reality may turn out to be quite different. A deep chasm lies ahead for Indian biosimilar manufacturers. The path they seek to travel will reveal the biggest hurdles they are ever likely to face. This journey, executed with strategic foresight and meticulous planning, however, could lead to a bloom they can fully harvest.